Clinical Trials Logo

Filter by:
NCT ID: NCT05838235 Not yet recruiting - Marfan Syndrome Clinical Trials

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome

M&M's
Start date: May 2023
Phase: N/A
Study type: Interventional

This research study aims to evaluate the effect of a 6-month adapted physical activity program (APA) on the endurance capacities (evaluated as the maximum oxygen consumption [VO2 peak] on a cardiopulmonary exercise test) of children and adolescents with Marfan syndrome or related.

NCT ID: NCT05835973 Not yet recruiting - Ulcerative Colitis Clinical Trials

Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.

RECIDREAM
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients. Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares. The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare. Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.

NCT ID: NCT05835804 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers

NIVOCHIMLOC
Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Patients with locally recurrent squamous-cell carcinoma of the head and neck (SCCHN) after Chemotherapy and immunotherapy have a very poor prognosis and limited therapeutic options. Intratumoral chemotherapy (ITC) with cisplatin and epinephrine in order to increase the local cisplatin retention lead to a 50 % response rate in several studies but was given up due to the poor local tolerance with frequent necrosis of the peritumoral tissues. Gemcitabine, carboplatin and paclitaxel (GCP) are used in advanced SCCHN. These chemotherapies seem to be interesting options for intratumoral infusion: their different effect could lead to avoid chemotherapy resistance with a good tolerance profile, without tissue necrosis profile. The other major option for recurrent SCCHN is immunotherapy by Nivolumab, an anti PD-1 with a 13% mediane response rate. Nevertheless, the failure of this treatment stay unclear, but immunosuppressive action of the tumour is suspected. The presence of tumoral antigen could lead to better response to immunotherapy; association of chemotherapy and immunotherapy seems a promosing association to avoid treatment resistance as cytotoxic release tumoral antigen; it could also be associated to an abscopal effect. The aim of the study is to evaluate the efficacy of ITC using GCP in LOCAL recurrent SCCHN treated by nivolumab.

NCT ID: NCT05835622 Not yet recruiting - Multiple Sclerosis Clinical Trials

Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.

EXHOMESEP
Start date: May 2, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to evaluate the effectiveness of home use of a lightweight robotic lower limb exoskeleton as a walking aid device on quality of life in patients with multiple sclerosis with gait disorders. Participants will wear an exoskeleton (Keeogo) for 8 weeks at home during the experimental phase. This phase is compared to an 8-week control phase at home with advice on regular physical activity adapted to their abilities.

NCT ID: NCT05832762 Not yet recruiting - Clinical trials for Ischemic Stroke, Acute

Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion Within 24 Hours of Last Seen Well (ETICA)

ETICA
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Our main hypothesis is that acute EVT associated with best medical treatment is superior to best medical treatment alone, for improving clinical outcomes at 90 days, in patient with mild or severe AIS and diffusion-perfusion or clinical-imaging mismatch, secondary to CICAO.

NCT ID: NCT05831371 Not yet recruiting - Alzheimer Disease Clinical Trials

Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET

EPITEP
Start date: May 2, 2023
Phase:
Study type: Observational

Etiology and cognitive prognosis in late onset epilepsy differ from young adults epilepsy. At the epilepsy onset, this is crucial to detect potential curative/treatable brain disorders. After classical investigation including morphological brain imaging, EEG, clinical assessment, which added value may have brain FDG PET in the diagnosis and prognosis evaluation?

NCT ID: NCT05830864 Not yet recruiting - Clinical trials for Refractory Status Epilepticus

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

I-Seizure
Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

NCT ID: NCT05830760 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Expression of Sodium-glucose Co-transporter 2 in Human Heart

SGLT2-MICRA
Start date: June 2023
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

NCT ID: NCT05825131 Not yet recruiting - Clinical trials for Sanfilippo Syndrome Type C

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

MPSIIIC
Start date: June 10, 2024
Phase:
Study type: Observational [Patient Registry]

This study is planned to document, through retrospective and prospective data collection, syndrome progression in children and young adults with MPS IIIC.

NCT ID: NCT05823025 Not yet recruiting - Vascular Stiffness Clinical Trials

Withings Study to Analyze the Accuracy of Pulse Wave Velocity Measurement With Bathroom Scales (WIVOP-Scales)

WIVOP-Scales
Start date: May 2, 2023
Phase:
Study type: Observational

The aim of this study is to evaluate the diagnostic performance of Withings bathroom scales WBS08 and WBS12 to measure PWV (Pulse Wave Velocity).